Key result
Vaccination with attenuated poliomyelitis virus completely protected 18 monkeys against intracerebral viral challenge and was safely administered to two human subjects without systemic ill effects.
Why the study?
Does vaccination with attenuated poliomyelitis virus protect against infection in monkeys and is it safe in humans?
Population
18 Macacus rhesus monkeys and 2 human subjects
Comparison
Subcutaneous and intracutaneous injections of… vs Unvaccinated controls (for monkeys)
Design
Preclinical
Follow-up
about one month after the last dose of vaccine (for monkeys)
Authors
Loading...
Supports progression to human trials for attenuated poliomyelitis vaccine; leaves open demonstration of clinical efficacy and durability.
Does vaccination with attenuated poliomyelitis virus protect against infection in monkeys and is it safe in humans?
Early preclinical and human case evidence demonstrating the potential efficacy and safety of an attenuated poliomyelitis vaccine.
Kolmer et al. (1935) studied Acute anterior poliomyelitis (n=20). Attenuated poliomyelitis virus vaccine in sodium ricinoleate vs. Unvaccinated controls was evaluated on Development of infection following intracerebral injection of infective virus. Vaccination with attenuated poliomyelitis virus completely protected 18 monkeys against intracerebral viral challenge and was safely administered to two human subjects without systemic ill effects.